Societal preferences for adjuvant melanoma health states: UK and Australia

BACKGROUND: No studies have measured preference-based utility weights for specific toxicities and outcomes associated with approved and investigational adjuvant treatments for patients with resected high-risk melanoma. METHODS: A cross-sectional study was conducted in the United Kingdom and Australia to obtain utilities for 14 adjuvant melanoma health states. One-on-one interviews were conducted using standard gamble; utility weights range from 0.0, dead, to 1.0, full health. Supplemental risk questions also were asked. RESULTS: Among 155 participants (52% male; mean age, 46 years) “adjuvant treatment no toxicities” (0.89) was most preferred, followed by “induction treatment” (0.88), and “no treatment” (0.86). Participants least preferred “cancer recurrence” (0.62); the utility for “cancer recurrence and 10-year survival with treatment” was 0.70. Disutilities for grade 2 toxicities ranged from −0.06 for fatigue to −0.13 for hypophysitis. The mean maximum acceptable risk of a life-threatening event ranged from 30% for a 6% increase in the chance of remaining cancer free over 3 years to 40% for an 18% increase; Australian respondents were willing to take higher risks. CONCLUSION: Reproducible health utilities for adjuvant melanoma health states were obtained from the general population in two countries. These utilities can be incorporated into treatment-specific cost-effectiveness evaluations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3673-y) contains supplementary material, which is available to authorized users.